Cervical intraepithelial neoplasia

Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023

These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.

Key Points: 
  • These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
  • Anemia is the most common adverse effect of CD47-targeting molecules, since red blood cells also express CD47.
  • Moreover, modifying the RNA sequence of the prospective anti-CD47 molecule is far more efficient than engineering the final protein product.
  • Our platform has made it possible for Nutcracker to lay a strong and early foundation for our future therapeutic work.”

Daré Bioscience Completes Previously Announced Equity Financing

Retrieved on: 
Tuesday, September 5, 2023

The aggregate gross proceeds to Daré, before deducting offering expenses payable by Daré, were $7.0 million.

Key Points: 
  • The aggregate gross proceeds to Daré, before deducting offering expenses payable by Daré, were $7.0 million.
  • The closing occurred on September 1, 2023.
  • “This financing strengthened our balance sheet, providing cash to help us deliver on important portfolio milestones this year,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • A pharmaceutical approach could provide women with an important alternative to surgery to treat this condition.”
    Daré’s completed equity financing included minority participation by an investor affiliated with Douglas.

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

Retrieved on: 
Tuesday, September 5, 2023

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.

Key Points: 
  • The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • As part of the primary objective of immunogenicity, data showed sustained HPV-antibody responses at 10 years after the third dose in boys and girls.
  • With the exception of cervical cancer, there is no routinely recommended screening for the detection of HPV-related cancers.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

Nutcracker Therapeutics Demonstrates Immunotherapeutic Potency of Lead mRNA Candidate at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023

Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).

Key Points: 
  • Nutcracker Therapeutics , Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented two posters showcasing the latest preclinical data for the company’s lead oncology mRNA therapeutic, NTX-250, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Fla. (April 14-19).
  • The lead indication for NTX-250 is cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection, which can progress to cervical cancer if left untreated.
  • More than 90 percent of cervical cancer and CIN cases are linked to HPV infection, with HPV16 as the most prevalent high-risk strain.
  • Lawrence Fong and David Oh at the University of California, San Francisco — which mapped shared tumor antigen reactivity using nanoparticle-encapsulated mRNA in prostate cancer patients.

Cervical Dysplasia Market is expected to generate a revenue of USD 789.32 Million by 2030, Globally, at 7% CAGR: Verified Market Research®

Retrieved on: 
Monday, January 30, 2023

JERSEY CITY, N.J. , Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Cervical Dysplasia Market" By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.

Key Points: 
  • JERSEY CITY, N.J. , Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, " Cervical Dysplasia Market " By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.
  • The "Global Cervical Dysplasia Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Cervical Dysplasia Market" study report will provide valuable insight with an emphasis on the global market.
  • Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.
    Based on the research, Verified Market Research® has segmented the global Cervical Dysplasia Market into Diagnostic, End-User, and Geography.

Cervical Dysplasia Market is expected to generate a revenue of USD 789.32 Million by 2030, Globally, at 7% CAGR: Verified Market Research®

Retrieved on: 
Monday, January 30, 2023

JERSEY CITY, N.J., Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Cervical Dysplasia Market" By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.

Key Points: 
  • JERSEY CITY, N.J., Jan. 30, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, " Cervical Dysplasia Market " By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), and By Geography.
  • The "Global Cervical Dysplasia Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Cervical Dysplasia Market" study report will provide valuable insight with an emphasis on the global market.
  • Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.
    Based on the research, Verified Market Research® has segmented the global Cervical Dysplasia Market into Diagnostic, End-User, and Geography.

Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022

Retrieved on: 
Friday, November 11, 2022

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.

Key Points: 
  • Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting.
  • NTX-250 is being developed for tumors driven by HPV16, which includes cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN).
  • Its been our long-held belief that the RNA drug class presents a unique opportunity to create safe and effective immunotherapies.
  • The preclinical data we presented today is compelling in this regard, and shows that NTX-250 is able to induce a strong immune response and completely regress tumors in a murine model.

Global Gynecology Partnering Deal Trends, Players and Financials Report/Directory 2010-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022

The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gynecology Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 490 gynecology deals.
  • The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.
  • Global Gynecology Partnering 2010 to 2022 includes:
    In Global Gynecology Partnering 2010 to 2022, available deals and contracts are listed by:

2021 Worldwide Gynecology Partnering Deals Report - Featuring Osivax, Fannin and DySIS Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021

The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gynecology Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Gynecology Partnering 2010-2021: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
  • Global Gynecology Partnering 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide.
  • In Global Gynecology Partnering 2010 to 2021, available deals and contracts are listed by: